MedWatch

This company will profit from major patent expirations

It is estimated that patent expirations will cost the pharmaceutical industry a staggering 35.5 billion dollars I 2012, but one US company could benefit greatly from the patent cliff.

In 2011 the total value loss from patent expirations was at 20.4 billion dollars, and in 2012 that number is expected to increase by 74 % to 35.5 billion dollars.

But while the major players in the pharmaceutical industry face great challenges because of the pipeline drought, US company CVS Caremark will actually profit from the many patent expirations.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier